trending Market Intelligence /marketintelligence/en/news-insights/trending/IxZPrWhBvoOtgt3UKk666g2 content esgSubNav
In This List

Foamix files for US FDA approval of rosacea treatment

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


Foamix files for US FDA approval of rosacea treatment

Foamix Pharmaceuticals Ltd. has submitted a new drug application to the U.S. Food and Drug Administration seeking approval for its experimental skin condition drug FMX103.

If approved, FMX103 would treat moderate-to-severe papulopustular rosacea in adults, a condition characterized by redness and visible blood vessels in the face. Rosacea, often mistaken for acne, can also cause small, red, pus-filled bumps to form.

The Israeli dermatology company's application is based on positive data from two late-stage studies, Foamix said in an Aug. 5 press release.

According to Foamix, approximately 16 million individuals in the U.S. have rosacea, and about 85% experience sensitivity to the available treatment options.